Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;11(1):69-91.
doi: 10.1586/1744666X.2015.991315. Epub 2014 Dec 18.

Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future

Itay Raphael  1 , Johanna Webb, Olaf Stuve, William Haskins, Thomas Forsthuber
Affiliations
Review

Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future

Itay Raphael et al. Expert Rev Clin Immunol. 2015 Jan.

Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system, which affects over 2.5 million people worldwide. Although MS has been extensively studied, many challenges still remain in regards to treatment, diagnosis and prognosis. Typically, prognosis and individual responses to treatment are evaluated by clinical tests such as the expanded disability status scale, MRI and presence of oligoclonal bands in the cerebrospinal fluid. However, none of these measures correlates strongly with treatment efficacy or disease progression across heterogeneous patient populations and subtypes of MS. Numerous studies over the past decades have attempted to identify sensitive and specific biomarkers for diagnosis, prognosis and treatment efficacy of MS. The objective of this article is to review and discuss the current literature on body fluid biomarkers in MS, including research on potential biomarker candidates in the areas of miRNA, mRNA, lipids and proteins.

Keywords: autoimmunity; biomarker; experimental autoimmune encephalomyelitis; multiple sclerosis; prognosis; therapy.

PubMed Disclaimer

References

    1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85(3):299–302. - PubMed
    1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683–747. - PubMed
    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952. - PubMed
    1. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Annals of neurology. 2009;65(3):239–248. - PubMed
    1. Hafler DA. Multiple sclerosis. The Journal of clinical investigation. 2004;113(6):788–794. - PMC - PubMed

Publication types